Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
81.70
-3.35 (-3.94%)
Apr 28, 2026, 4:08 PM HKT
Market Cap 16.80B
Revenue (ttm) 197.25M
Net Income (ttm) -235.27M
Shares Out 197.56M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 335,155
Average Volume 1,277,217
Open 84.95
Previous Close 85.05
Day's Range 81.05 - 86.65
52-Week Range 44.72 - 97.50
Beta n/a
RSI 51.48
Earnings Date May 29, 2026

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.